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Abstract
Background
Diabetes peer support, where one person with diabetes helps guide and support others,
has been proposed as a way to improve diabetes management. We have tested whether
different diabetes peer support strategies can improve metabolic and/or
psychological outcomes.
Methods
People with type 2 diabetes (n = 1,299) were invited to participate as either ‘peer’ or ‘peer
support facilitator’ (PSF) in a 2x2 factorial randomised cluster controlled trial across rural
communities (130 clusters) in England. Peer support was delivered over 8–12 months by
trained PSFs, supported by monthly meetings with a diabetes educator. Primary end point
was HbA1c. Secondary outcomes included quality of life, diabetes distress, blood pressure,
waist, total cholesterol and weight. Outcome assessors and investigators were masked to
arm allocation. Main factors were 1:1 or group intervention. Analysis was by intention-to-
treat adjusting for baseline.
Results
The 4 arms were well matched (Group n = 330, 1:1(individual) n = 325, combined n = 322,
control n = 322); 1035 (797%) completed the mid-point postal questionnaire and 1064
(819%) had a final HbA1c. A limitation was that although 92.6% PSFs and peers were in
telephone contact, only 61.4% of intervention participants attended a face to face session.
Mean baseline HbA1c was 57 mmol/mol (74%), with no significant change across arms.
Follow up systolic blood pressure was 23mm Hg (0.6 to 4.0) lower among those allocated
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Conclusions
Group diabetes peer support over 8–12 months was associated with a small improvement
in blood pressure but no other significant outcomes. Long term benefits should
be investigated.
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Introduction
Diabetes leads to morbidity and premature death [1] and is associated with depression, distress
and reduced quality of life [2–4]. A range of personal, psychological, social and organizational
barriers to diabetes care have been identified [5]. Behavioral interventions attempting to ad-
dress metabolic, mental health and psychological issues have shown varying success [6].
One group of interventions to improve diabetes outcomes involves assistance from another
person with the condition: such ‘peer supporters’ have often faced similar problems [7]. Sup-
port is characterised by empathy, and an approach that shares practical aspects of managing di-
abetes in day-to-day life i.e. the ‘how to do’ rather than the ‘what to do’. Peer support can
involve individual or group approaches face-to-face, telephone and internet contacts [8].
Randomised controlled trial (RCT) evidence of a beneficial effect from peer support in dia-
betes remains inconsistent, with possible influences on biomedical outcomes such as glucose
control, blood pressure (BP), dyslipidaemia and weight as well as mental health outcomes such
as depression and diabetes distress [9]. However, these trials had limitations, differences in de-
sign and the extent of implementation extent [9]. Peers for Progress recently funded RCTs of
peer support across 8 sites [10]. The largest of these, the randomised controlled trial of Peer
Support In type 2 Diabetes (RAPSID), was designed to test the efficacy of individual and/or
group peer support, within the context of a health system providing comprehensive primary
care.
The study interventions were successfully piloted and demonstrated that the overall study
design was appropriate for roll out into an RCT [11]. However, during the pilot, there was a
tendency for the peers selected to be trained to adopt a ‘quasi health professional’ role (‘put on
a pedestal’), rather than the desired non directive, facilitatory role. To address this, it was decid-
ed to firstly change the title from “peer supporter” to “peer support facilitator” (PSF) and sec-
ondly to replace the GP/practice nurse recommendation approach to asking all participants for
an expression of interest to be a PSF. The second change, to address delays in the delivery of
the PSF training by requests for diabetes education, was to provide diabetes education prior to
the training of PSFs.
Both these recommendations required some operational changes and were fully imple-
mented. We now describe the results of the RCT comparing different diabetes peer support
strategies.
RAPSID: RCT of Diabetes Peer Support
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Methods
The protocol for this trial and supporting CONSORT 2010 checklist are available as supporting
information; see S1 Protocol and S1 CONSORT Checklist.
Design Overview, setting and participants
RAPSID (ISRCTN66963621) was a 2x2 factorial cluster RCT comparing 4 intervention groups:
Controls, 1:1 (individual) peer support group peer support, or combined group and 1:1 peer
support among patients with type 2 diabetes. Participants had their diabetes for at least 12
months and those with dementia or psychotic illness were excluded. Participants were re-
cruited from communities across Cambridgeshire and neighbouring areas of Essex and Hert-
fordshire. Communities were defined by local government (‘parish council’) boundaries.
Registration was delayed until after recruitment had commenced for internal administrative
reasons.
Recruitment commenced with posters at community venues, followed by mail invitations
through 62 general practices, a hospital clinic and Diabetes UK members. Potential partici-
pants were mailed three sequential invitations to express an interest in joining the trial and
finding out about becoming a peer support facilitator (PSF) i.e. a person who supported others.
Attendance at a local venue was arranged. The patient recruitment phase was from 02/06/11 to
12/04/12, and follow-up from 10/09/12 to 29/08/13.
Randomization and Interventions
All participants were invited to a 35 hour group education workshop, facilitated by a diabetes
educator. This was to allow participants to begin the study with a reasonable understanding of
diabetes, and focus the trial their participation in the trial on peer support rather than diabetes
education. Attendance at the workshop was not compulsory for continuation in the trial.
Clusters were then randomised electronically in blocks of four (one cluster in each arm) by
the statistician who had no trial involvement. Randomisation occurred once all clusters in the
block were ready to proceed. All measurement staff were blind to the randomisation.
Table 1 describes PSF selection, the 2-day training and PSF support arrangements. The ap-
proach of selecting PSFs from those expressing an interest, rather than by nomination, was de-
veloped after the pilot study found that inviting general practitioners to nominate PSFs made
them seem less like peers and more like health workers [11]. PSFs were normally from the
same local community as their peers, in a ratio of approximately 1:5, with clusters including up
to 15 participants in total. Where there were insufficient volunteers for the PSF role, further
participants from within the cluster were approached, or those from other areas (in the same
arm) were asked to assist.
The intervention was delivered in 2 phases: an initial 4–6 months discussing 3 core aspects:
(1) how to address barriers to care/practical issues arising from living with diabetes (2) social
and emotional aspects of diabetes and (3) the health care received. PSFs were asked to be non-
directive and deploy the listening skills explored during the PSF training in order to support
peers in their efforts to attain better control over their diabetes and its effects on everyday life.
In the second phase, PSFs were invited to continue with the same themes, but to discuss other
topics not yet covered and consider inviting speakers.
PSFs were offered a mobile phone and reimbursed for hiring local venues for intervention
sessions and refreshments. A ‘RAPSID nurse’met with groups of PSFs within each intervention
arm, in each of four geographical areas on a monthly basis. These meetings enabled PSFs to
share positive and challenging experiences, generate potential solutions, discuss clinical issues
that arose and keep the delivered content of the interventions in a standardised form. A
RAPSID: RCT of Diabetes Peer Support
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RAPSID nurse was also contactable by telephone during office hours if PSFs had pressing con-
cerns. Finally, an independent committee of four diabetes patients reviewed all study proce-
dures and provided the study team with advice where needed.
PSFs were asked to keep records of telephone contacts and meetings with their peers. They
were also provided with diaries and encouraged to write reflections on their experiences of de-
livering the intervention. Even if a peer was unable to attend a meeting, PSFs were asked to at-
tempt to make contact and discuss arrangements. Contact between peers within the same trial
arm was not recorded. Throughout the trial, care was taken not to introduce those in different
arms of the study to each other. Costs were collected from PSF claims and invoices.
Outcomes and Follow-up
A research nurse obtained consent, checked a self-completed questionnaire, measured weight,
height, waist circumference, BP and collected blood (HbA1c, lipids) using standardised meth-
odology/ equipment following training by the local Medical Research Council Epidemiology
Table 1. PSF selection, training and support programme and Education session content.
PSF Selection
PSFs were selected through:
• Postal expression of interest
• Not ﬂagged as unsuitable by their general practice team
• Unremarkable Criminal Record Bureau check
• Attended the education session
• Appeared ﬂexible, adaptable and non-judgemental to observers at the measurement, education and
training sessions
PSF training
Training of PSFs was undertaken separately for the 3 intervention programmes, lasted 2 days and included
• An introduction to the trial
• A session exploring the role of the peer supporter
• Motivational interviewing techniques
• Communication with health professionals
• Conﬁdentiality and data protection
• A series of role-plays to practice boundary-setting, effective listening, dealing with difﬁcult situations such
as depression or alcoholism, and the limitations of the role (i.e. not offering knowledge or diagnosing
problems)
• Safety (e.g. lone worker policy if 1:1 or combined peer support arms)
• Leading a group (if group or combined peer support arms)
• Provision of a programme manual and a booklet describing local services
Duration of meetings (1:1 meetings-up to 1 hour; group meetings up to 15 hours.)
PSF support
• Monthly meetings with a RAPSID Nurse
• Bimonthly newsletters
Telephone access to a RAPSID nurse between meetings
Education Session content (all participants)
• Identifying carbohydrates and understanding portions
• Truths and myths about diabetes
• Know your numbers and medications
• Keeping active and looking after your feet)
Questions and answers
doi:10.1371/journal.pone.0120277.t001
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Unit. The questionnaire included socio-demographic and clinical questions (eg medications),
and measures of depression (PHQ8), quality of life (EQ5D), diabetes self-efficacy, the Revised
Diabetes Knowledge Scale (RDKS), diabetes distress, and medication adherence [12–17]. IFCC
aligned HbA1c (High performance liquid chromatography, Tosoh G7, Tokyo, Japan) and lipid
measurements (Dimension RxL Max Clinical Chemistry System, Siemens, Erlangen, Germany)
were undertaken in one ‘CPA’ accredited laboratory to minimise variation in both the primary
outcome, HbA1c and total cholesterol, a secondary outcome.
Outcomes were measured using postal questionnaires at 4–6 months and face-to-face mea-
surements and questionnaires after 8–12 months. Clinical data was extracted where data re-
mained missing, if collected within three months of the expected measurement date.
Statistical Analysis
Sample size calculation. The trial tested the main effects of 1:1 peer support versus no
1:1 peer support (factor 1) and group versus no group peer support (factor 2). With a predicted
mean cluster size of 106 participants and an intra-cluster correlation of 0037 based upon an
unpublished estimate from a previous study [18] for HbA1c, a design effect of 136 was antici-
pated. A sample size of 1,250 participants from 106 clusters, after allowing 6 clusters to drop
out and a further 10% participant loss to follow-up, would leave 1,060 participants in 100 clus-
ters for primary outcome analysis. The practical aspects relating to the number of likely avail-
able clusters, and numbers likely to be recruited from within a cluster, resulted in non-rounded
power estimates. Based on a standard deviation for HbA1c of 1.25, this provided (two-sided
tests, p<005), 91% power to detect a difference of 03% (3 mmol/mol) in mean HbA1c for
each factorial main effect, 88% power to detect a difference of 04% (4 mmol/mol) between any
two arms in the case of an unexpected interaction between the factorial effects [19], and 82%
power to detect a 03% (3 mmol/mol) difference between combined intervention arms and the
control arm. For questionnaire outcomes with the same intra-cluster correlation, based on 880
participants assuming a reduced 75% follow-up rate, there was 90% power to detect effect size
differences of 025sd for factorial main effects, and 035sd for pair-wise comparisons. Where
baseline of an outcome was collected, there was improved precision of intervention effects due
to the adjustment for baseline in the analysis.
Statistics. Analyses were on an intention to treatment (ITT) basis, two-sided and assessed
at p<005. Each continuous outcome was analysed using linear mixed effects regression mod-
els (using the nlme package in R software [20]) with cluster as the random effect, and adjusting
for the baseline of the outcome using the missing indicator method to include any participants
for whom the baseline was missing [21]. Homoscedastic variances were not assumed; but in-
stead residual variances were allowed to be different within each trial arm. Main effects were in-
cluded to test for the two factors after confirming no significant interaction between them [22].
These were then replaced by a term to contrast the combined intervention arms with the con-
trol arm to estimate the effect of any peer intervention. Patients with missing outcome data
were excluded. A sensitivity analysis including all patients was conducted by using multiple im-
putation (based on 50 imputed datasets), which did not change the conclusions of the primary
outcome analysis. Any missing outcome values were assumed to be missing at random. In
order to understand the results of the ITT analysis more fully, an a priori per protocol (PP)
population was defined by excluding those attending no meetings in the intervention arms. At-
tenders were significantly older, more highly educated, with lower body mass index (BMI) and
smoking prevalence. A pre-planned subgroup analysis consisted of the same analyses but
among participants with an HbA1c above 8% (64mmol/mol)).
RAPSID: RCT of Diabetes Peer Support
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All outliers of HbA1c>4 sd from the mean were included in the primary analysis, but then
excluded as part of a sensitivity analysis. An additional sensitivity analysis involved performing
the ITT analyses based on the per protocol population. SPSS version 21 was used for calculat-
ing descriptive statistics (IBM Corp, Armonk, NY, USA). Ethics approval was received from
the Cambridgeshire 2 Research Ethics Committee (08/10/10), and all participants gave signed
informed consent. The authors confirm that all ongoing and related trials for this intervention
are registered.
Results
Recruitment
The CONSORT diagram (Fig. 1) shows that recruitment and cluster number exceeded their
targets. Follow-up met expectations. Baseline data for the 4 arms were well matched (Table 2).
The majority reported antihypertensive (820; 63%), lipid-lowering (847; 65%) and diabetes
medication (991; 76%). Compared with those without, those with an endpoint Hba1c were
older (mean (sd) 65 (9) vs. 63(10) years p = 0018), had longer diabetes duration (9 (11) vs.
8 (8) years p = 0.016), lower BMI (31.9 (6.8) vs. 33.6(6.7) kg/m2 p<0.001) and were more likely
to be treated with anti-hyperglycaemic tablets (81.6% vs. 73.2% p = 0004), hypertension
Fig 1. Recruitment and follow-up of participants.
doi:10.1371/journal.pone.0120277.g001
RAPSID: RCT of Diabetes Peer Support
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treatment (66.2 vs. 59.4% p = 0004) and dyslipidaemia treatment (685% vs. 607% p = 0021)
at baseline. The actual intra-cluster correlation coefficient at baseline was calculated to be 0.028
with a mean cluster size of 10 participants per cluster.
Intervention
167 PSFs were trained, of whom, 127 facilitated at least one meeting. PSFs were available for
95/98 (969%) intervention clusters (Table 2). Table 1 also shows the number of clusters where
interventions took place over5 months. There was no significant difference between inter-
vention arms in the number of months of intervention. Reporting data indicated that 90/98
(918%) intervention clusters covered the three core aspects of the intervention. Most (926%)
peers and PSFs had been in mutual contact, but only 614% (592/977) of intervention partici-
pants attended an actual peer support session, with a mean number of attendances of 37, with
others in telephone or e-mail contact. Reasons for non-attendance included the time to initiate
Table 2. Baseline characteristics of RAPSID participants allocated to individual, group, combined or control peer support intervention and
intervention participation by cluster.
Control (n = 322) 1:1 (n = 325) Group (n = 330) Combined (n = 322)
Males 191 (593%) 189 (582%) 216 (655%) 189 (587%)
Mean (SD) age (years) 646 (103) 652 (89) 652 (102) 653 (93)
Median (IQR) duration of diabetes (years) 65 (30–120) 70 (30–120) 70 (30–120) 60 (30–110)
Ethnic minority 22 (69%) 24 (75%) 23 (71%) 23 (73%)
Completed tertiary education 74 (246%) 82 (266%) 92 (298%) 77 (257%)
Professional/managerial 216 (686%) 204 (646%) 212 (671%) 209 (672%)
Married/cohabiting 239 (766%) 229 (720%) 250 (791%) 235 (768%)
Self-reported smoking 37 (118%) 28 (88%) 28 (88%) 26 (84%)
Insulin treated 47 (146%) 62 (191%) 53 (161%) 56 (174%)
Diabetes Tablets 252 (783%) 275 (846%) 260 (788%) 248 (770%)
Insulin and tablets 35 (109%) 53 (63%) 41 9124%) 39 (121%)
Hypertension Treatment 192 (611%) 217 (680%) 202 (631%) 209 (674%)
Dyslipidaemia Treatment 198 (631%) 218 (683%) 213 (666%) 218 (703%)
BMI kg/m2 321 (61) 327 (64) 319 (58) 321 (58)
HbA1c mmol/mol 568 (127) 576 (133) 581 (130) 561 (128)
HbA1c % 7.3 (1.3) 7.4 (1.3) 7.5 (1.3) 7.3 (1.3)
SBP mm Hg 1403 (181)/ 1406 (183)/ 1411 (173)/ 1394 (167)/
DBP mm Hg 755 (106) 761 (97) 756 (102) 764 (95)
Waist cm 1085 (136) 1100 (147) 1096 (139) 1086 (136)
Total Cholesterol mmol/l 441 (107) 439 (101) 433 (107) 441 (106)
Intervention/Participation
Number of PSFs in cluster 0 61 57 49
Clusters with intervention 0/32 31/33 33/33 31/32
Contacted/Offered support 0 284(874%) 321(973%) 299(929%)
Attended at least once 0 175 (538%) 219 (664%) 198 (615%)
All 3 Peer support activities delivered# 0 31/33 30/33 29/32
Clusters with 5 months of intervention 26/33 (78.8%) 27/33 (81.8%) 25/32 (78.1%)
Numbers are n (%) or mean (SD);
# (1) how to address barriers to care/practical issues arising from living with diabetes (2) social and emotional aspects of diabetes and (3) the health
care received
doi:10.1371/journal.pone.0120277.t002
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local peer support (related to delays in honorary contract documentation, Criminal Record Bu-
reau checks and training), sickness, changes in personal circumstances and moving house.
New activities initiated in the second phase of the intervention included table tennis, carpet
bowling, golf and walking. Average estimated annual intervention costs per cluster are shown
in Table 3. Costs varied widely, particularly venue costs.
Outcomes
There was greater follow up of HbA1c among the controls than the intervention arms (p =
0002) (Fig. 1). Tables 4 and 5 show the ITT and per protocol analyses with no significant inter-
vention effect on HbA1c, diastolic BP, weight, total cholesterol, diabetes knowledge, depres-
sion, quality of life, adherence or self-efficacy. However, the group main effect was associated
with a significantly lower systolic BP (−231, 95% CI −401 to −061 mm Hg, p = 0008).
Among those attending at least once, the group main effect was associated with a −3x05 (95%
CI −497 to −112, p = 0002) mm Hg lower systolic and a −071 (95% CI −142 to −001, p =
0048) cm lower waist circumference (although the waist results became −070 (95% CI −140
to 001) cm p = 0053) after removing outliers more than 4 sd from the mean). Only 272 partic-
ipants had an HbA1c above 8% (64mmol/mol) and no significant change was found in HbA1c
(1:1 +059(95% CI −336 to 455); group +002 (95% CI −393 to 398); overall −002 (95% CI
−457 to − 453) mmol/mol) or any of the other measures on follow up. There were no signifi-
cant differences in self-reported medication changes between interventions. Diabetes distress
improved significantly with the 1:1 main effect (−042 (95% CI −075 to −010, i.e. approxi-
mately 6% reduction) in the per protocol analysis.
Discussion
There was no significant change in HbA1c with any intervention. HbA1c was chosen as the
primary outcome when the lower target for payments to general practitioners under the
Table 3. Costs of the intervention.
Item Unit Cost (£) Units Total
Peer support meeting costs
Venue (not 1:1) £594 monthly £7128
Refreshments £178 monthly £2136
Mobile top up vouchers £323 monthly £3876
Peer support facilitator meeting costs
RAPSID nurse time £5731 Monthly Up to 20 clusters £3439
RAPSID nurse travel costs £301 Monthly Up to 20 clusters £181
Peer support facilitator training and material costs
PSF booklet and amenity booklet £467 Per cluster £467
PSF training trainer cost £28650 Per session Up to 10 clusters £2865
PSF training venue cost £5571 Per session Up to 10 clusters £557
PSF training catering cost £1086 £1086 £109
Roll out costs £20758
Assumes maximum number of clusters involved in training/PSF sessions With 15 participants attending/cluster = £1384/participant/year
Recruitment and coordination costs are not included Nurse is band 6 if works within a full multidisciplinary diabetes specialist service-
otherwise band 7 Peer support meeting costs are from PSF claims Booklet costs include those given to PSFs who did not subsequently act as a PSF.
Few PSFs used the RAPSID mobile phones, preferring to use their own, so only the ongoing costs are included.
doi:10.1371/journal.pone.0120277.t003
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Quality and Outcomes Framework (QOF) was 70% (53mmol/mol) [23]. This QOF target was
subsequently raised to 75% (58 mmol/mol): above the level for the majority of RAPSID partic-
ipants (RAPSID mean HbA1c 57 mmol/mol (74%)) making achievement of a change unlikely.
However, there was no change among those with an HbA1c8% (64 mmol/mol) either.
There were no significant differences between groups in change in self-reported diabetes medi-
cation, but detailed information on dose was not collected.
Group peer support was associated with a significant reduction in systolic BP, enhanced
among those attending the intervention. This degree of reduction in BP (2–3mmHg) would be
associated with a relative reduction in myocardial infarction by 2–4%, stroke by 4–6% and all-
cause mortality by 2–4% from observational data [24]. The mechanism for the BP reduction
was unlikely to be increased medication adherence as the Morisky scale remained unchanged.
It may be that the social support had direct effects on BP given the demonstrated links between
the two [25]. Another possibility is that there may have been a change in lifestyle as suggested
by the reduction in waist circumference observed in those who attended meetings. However,
we found that those attending the intervention, and therefore belonging to the per protocol
Table 4. Anthropometric and Biochemical Outcomes at follow-up for RAPSID participants allocated to individual, group, combined or control
peer support intervention.
Intention to Treat—Per Protocol (1 or more attendances)
All Control 1:1 Group Combined 1:1
Effect
Group
Effect
Any
intervention
1:1
Effect
Group
Effect
Any
intervention
N = 283*
(N = 283)
N = 264
(N = 157)
N = 272
(N = 195)
N = 245
(N = 176)
HbA1c follow
up*§
597
(135)
603 (144) 600 (135) 588 (130) 019
(−113 to
151)
−017
(−149 to
114)
−029 (−177
to 120)
−050
(−191 to
091)
−077
(−217 to
063)
−098 (−241
to 045)
SBP follow
up*
1383
(168)
1394
(162)
1365
(163)
1359 (165) 066
(−104 to
235)
−231
(−401 to
−061)
−069 (−272
to 135)
096
(−100 to
292)
−305
(−497 to
−112)
−117 (−331
to 098)
DBP follow up 752
(100)
748 (923) 739 (105) 750 (102) 005
(−104 to
113)
−046
(−155 to
062)
−066 (−189
to 058)
−031
(−155 to
094)
−114
(−238 to
011)
−109 (−243
to 026)
Pulse rate
follow-up ¤
740
(139)
736 (129) 736 (128) 742 (122) −046
(−180 to
088)
−019
(−152 to
115)
−075 (−231
to 081)
−002
(−011 to
006)
0004
(−008 to
009)
003 (−006 to
012)
Total
cholesterol
follow-up*
421
(098)
425 (090) 417 (095) 415 (095) −002
(−009 to
005)
−001
(−008 to
006)
001 (−007 to
009)
−060
(−217 to
097)
−022
−178 to
133)
−077 (−243
to 089)
Weight follow
up*
900
(172)
921 (196) 909 (181) 892 (170) 008
(−053 to
070)
−009
(−070 to
053)
−022 (−097
to 054)
003
(−066 to
072)
−026
(−095 to
044)
−020 (−096
to 056)
Waist follow
up* ¤
1079
(136)
1098
(148)
1075
(131)
1079 (134) 011
(−050 to
072)
−057
(−118 to
004)
−047 (−115
to 021)
043
(−026
113)
−071
(−142 to
−001) **
−024 (−097
to 050)
*Sample size N refers to the primary outcome HbA1c in the Intention-to-treat population. The per protocol population is in brackets. Range of N for
secondary outcomes are as follows
Control 240–291 (per protocol 240–291), 1:1 219–270 (141–159), Group 227–273 (174–195), Combined 202–257 (152–184)
** Result sensitive to outliers. Conclusion changed after removing outliers more than 4 sd from the mean. Group main effect became −070 (95% CI−140
to 001)
§ The model-based ICC for HbA1c at follow-up was calculated to be 0.043 for the primary Intention to treat analysis (including main effects terms only).
doi:10.1371/journal.pone.0120277.t004
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population, had significantly lower waist circumference at baseline (mean 108.3 versus 111.0,
t-test p = 0.005) suggesting lifestyle change may have contributed to the observed difference,
but no objective measures were used to assess this. Increased physical activity has previously
been found to be associated with a 3–5 mm Hg drop in systolic BP, without a significant drop
in diastolic BP [26]. There was no significant change in any of the other secondary outcomes.
Amongst those attending the 1:1 intervention (but not by intention to treat), there was a sig-
nificant reduction in diabetes distress. Why this occurred in the 1:1 group is unclear and war-
rants further work. There was no significant change in any of the other secondary outcomes
with the 1:1 peer support.
There are various reasons why the group approach may have been more effective than the
1:1 approach. These include the greater participation rates, the ability within a group for partic-
ipants to select the members with whom they prefer to establish supportive relationships
(whereas in a 1:1 interaction the relationship is dictated by study allocation), and also the ob-
servation that some groups undertook physical activity together.
Comparison with other studies
This is the largest ever RCT of diabetes peer support and the only study investigating both 1:1
and group peer support approaches. It is one of the few truly community action, rather than
health service/primary care, based RCTs. An impact on BP has been shown in some other stud-
ies [9]. One major Irish RCT in primary care demonstrated no significant metabolic impact
[27]: although the BP dropped 3–4 mmHg in their intervention group, it was not statistically
significant. A comparison between nurse management and peer support also showed a non-
Table 5. Psychosocial Outcomes at baseline and change at follow-up for RAPSID participants allocated to individual, group, combined or
control peer support intervention.
All Control
Baseline
N = 322
(N = 322)
1:1
Baseline
N = 325
(N = 175)
Group
Baseline
N = 330
(N = 219)
Combined
Baseline N =
322 (N =
198)
1:1
Effect
Group
Effect
Any
intervention
Per
protocol
1:1 Effect
Per
protocol
Group
Effect
Per protocol
Any
intervention
Diabetes
knowledge
(0–15)
103 (303) 102 (296) 105 (300) 103 (320) −013
(−047
to 021)
017
(−017
to 051)
005 (−035
to 045)
−005
(−044 to
033)
017
(−021 to
054)
020 (−019 to
059)
Depression
PHQ8 (0–24)
449 (501) 439 (513) 449 (492) 459 (460) −017
(−066
to 032)
−022
(−071
to 026)
−023 (−081
to 036)
−037
(−096 to
022)
005
(−053 to
064)
−027(−090
to 036)
Diabetes
Distress (4–
24) DDS-4
661 (405) 653 (412) 627 (322) 671 (427) −025
(−055
to 006)
013
(−018
to 043)
−011 (−046
to 025)
−043
(−076 to
−010)
022
(−011 to
055)
−017(−053
to 0200)
Quality of life
EQ-5D
(−011–1)
077 (027) 075 (030) 076 (026) 076 (027) 001
(−002
to 003)
000
(−002
to 002)
−001 (−003
to 002)
−000
(−003 to
003)
000
(−003 to
003)
−001 (−003
to 002)
Self-efﬁcacy
DSE-8 (8–
80)
584 (172) 563 (182) 576 (162) 570 (171) 140
(−012
to 292)
−029
(−181
to 123)
162 (−011
to 335)
170
(−016 to
355)
−005
(−190 to
180)
180 (−017 to
377)
Morisky
(Medical
adherence)
(0–4)
118 (112) 111 (114) 126 (114) 114 (112) −002
(−014
to 010)
002
(−010
to 014)
−001 (−015
to 013)
−002
(−015 to
012)
005
(−008 to
018)
−002(−016
to 013)
N refers to the maximum sample size in the Intention-to-treat population. Maximum sample size in the per protocol population is in brackets.
Range of N are as follows
Control 236–322 (per protocol 236–322), 1:1 215–325 (136–175), Group 212–330 (160–219), Combined 197–322 (145–198)
doi:10.1371/journal.pone.0120277.t005
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significant blood pressure reduction with peer support [28]. The recent RCT of 1:1 telephone
support in Hong Kong showed no benefits across the intervention cohort [29].
RAPSID included a cohort of patients who had metabolic results below or near national tar-
gets [23] had good access to primary care, were largely well-educated, and often from manage-
rial/professional occupations. How the intervention would impact on more disadvantaged
patients in the UK is unclear, but improvements in HbA1c have been shown among patients
with poor glucose control and diminished access to health care elsewhere [30], even when com-
pared with financial incentives [31].
Strengths and limitations
RAPSID was well-powered to test its hypothesis, not only because it achieved its recruitment
targets and size, but also because of high retention rates. The intervention was largely imple-
mented having established peer support and delivered the planned content in almost all areas.
However, a significant proportion of those invited did not participate and many participants
did not take up the peer support, in spite of signing up to do so, and being contacted to arrange
attendance. There were a range of hurdles to establishing peer support. In the 1:1 and com-
bined interventions, there were 3 clusters in which no PSF could be identified, and in some
clusters, there were insufficient to deliver the 1:1 intervention. Arranging a convenient time to
meet was often a challenge, particularly for the group arms, addressed by other trials through
telephone rather than face to face support [8]. A major hurdle was the time between the expres-
sion of interest and first intervention contact—this was largely due to the need to recruit suffi-
cient numbers for the cluster including the need to identify, train and ‘check’ the PSFs. By the
time the intervention was due to start, some participants had found other activities to interest
them, while others were unwell or had moved. Under 10% of those originally invited expressed
an interest in participating. We feel that this reflects that participation in RCTs and/or peer
support are not for all of those with type 2 diabetes: further research is needed to assess reach
outside of the RCT setting. However, in spite of the reduced uptake of the intervention within
the trial, there was still a significant reduction in systolic blood pressure, and it is conceivable
that greater uptake could have been associated with a greater impact. Either way, implemented
in the real world, this trial did not deliver an effect on HbA1c or indeed the other secondary
outcomes besides systolic blood pressure.
Even if participants attended the intervention, a significant proportion dropped out after
each meeting. This did not necessarily mean that peer support halted, as there was undocu-
mented evidence that contact between peers, and between peer and PSF, sometimes continued.
The effect of peer support is likely to be dose dependent, but it was not possible to reliably as-
sess the relationship between attendance and outcome within our study, because attendance
was only observed post-randomisation and participants were obviously not randomised ac-
cording to attendance level.
The probability of observing at least one false significant result was increased due to the rela-
tively high number of secondary outcomes analysed. The duration of the trial was relatively
short and impact over time may affect participants more or less, and in other ways, than found
in RAPSID.
Conclusion
Group, rather than 1:1 peer support, implemented with well-trained PSFs, supported and
linked with health services through an experienced diabetes educator, reduced systolic BP, but
not the primary outcome HbA1c, or other secondary outcomes, among English patients with
relatively good metabolic control and access to health care. Further, well-powered, longer term
RAPSID: RCT of Diabetes Peer Support
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efficacy and effectiveness studies would be helpful to confirm these findings and assess possible
benefits over time.
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